Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
IngevityMEX:NGVT 62 Debt-to-EBITDA is 4.45 as of Mar. 2026, which is 26% above its 10-year median of 3.53. GuruFocus rates MEX:NGVT with a GF Score™ of 62/100 and a GF Value™ of MXN852.06. The stock has 6 warning signs investors should review. Among 1,234 Chemicals companies, Ingevity ranks worse than 98.62% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Ingevity's Debt-to-EBITDA or its related term are showing as below:
MEX:NGVT'
s Debt-to-EBITDA Range Over the Past 10 Years
Min: 1.94 Med: 3.53 Max: 57.1
Current: 57.1
During the past 13 years, the highest Debt-to-EBITDA Ratio of Ingevity was 57.10. The lowest was 1.94. And the median was 3.53.
MEX:NGVT's Debt-to-EBITDA is ranked worse than 98.62% of 1234
companies
in the Chemicals industry
Industry Median: 2.16
vs MEX:NGVT: 57.10
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Ingevity Debt-to-EBITDA Related Terms
Ingevity Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Ingevity's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEX:NGVT vs KWR, MTX, ASH: Debt-to-EBITDA Comparison
For the Specialty Chemicals subindustry, Ingevity's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ingevity Debt-to-EBITDA vs Chemicals Industry
For the Chemicals industry and Basic Materials sector, Ingevity's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ingevity's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Ingevity (MEX:NGVT) has a Debt-to-EBITDA of 4.45 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ingevity. This is 26% above median its historical median of 3.53. Over the past decade, Ingevity's Debt-to-EBITDA has ranged from 1.94 to 57.10. According to the industry distribution chart, Ingevity ranks #1217 out of 1234 companies in the Chemicals industry, placing it in the top 98.6%.
Is Ingevity's Debt-to-EBITDA too high?
Ingevity's current Debt-to-EBITDA of 4.45 is 26% above median its 10-year median of 3.53. Over the past 10 years, this metric has ranged from a low of 1.94 to a high of 57.10. The Chemicals industry median Debt-to-EBITDA is 2.16. Ingevity's value of 4.45 is 106% above this industry median. Based on the distribution chart, Ingevity ranks #1217 out of 1234 companies in the Chemicals industry, which is in the bottom quartile relative to peers. Overall, Ingevity has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ingevity's Debt-to-EBITDA compare to KWR and MTX?
According to the Chemicals industry distribution chart, Ingevity ranks #1217 out of 1234 companies for Debt-to-EBITDA. This places Ingevity in the lower half of its industry. The industry median Debt-to-EBITDA is 2.16. Ingevity's value of 4.45 is 106% above this benchmark. Historically, Ingevity's own Debt-to-EBITDA has ranged from 1.94 to 57.10 over the past decade. While the company's 10-year median is 3.53 vs. the industry median of 2.16, Ingevity has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Chemicals company?
The median Debt-to-EBITDA among Chemicals companies is 2.16, based on 1,234 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Ingevity's current Debt-to-EBITDA of 4.45 is 106% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Ingevity. For the Chemicals industry, the median Debt-to-EBITDA is 2.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ingevity's current Debt-to-EBITDA is 4.45, which is 26% above median its own 10-year median of 3.53. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ingevity stock overvalued right now?
Ingevity (MEX:NGVT) has a current Debt-to-EBITDA of 4.45. The stock's GF Value™ is MXN852.06, compared to a current price of MXN1,430.00 — trading 67.8% above its estimated fair value. The current Debt-to-EBITDA is 4.45, which is 26% above median its 10-year median of 3.53 and 106% above the Chemicals industry median of 2.16. Ingevity's overall GF Score™ is 62/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Ingevity (MEX:NGVT), the current Debt-to-EBITDA is 4.45 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ingevity (MEX:NGVT) Overvalued in 2026?
Based on GuruFocus' analysis, Ingevity stock appears to be overvalued.
The current stock price of MXN1,430.00 is trading 67.8% above its estimated GF Value™ of MXN852.06.
Key valuation signals for MEX:NGVT:
Debt-to-EBITDA: 4.45 (26% above median its 10-year median of 3.53)
GF Value™: MXN852.06 vs. price of MXN1,430.00 (67.8% above fair value)
Industry Position: 106% above the Chemicals median (#1217 of 1234)
No single metric tells the full story. See the MEX:NGVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
62GF Score
Get the complete analysis for MEX:NGVT
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NGVT has been successfully added to your 
